AS

Alpesh Suryakant Shah

Active Director Designated Partner DIN 11348312
DIN 11348312 First appointment Oct 2025 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2025
Shareholding value •••• Premium profile

About Alpesh Suryakant Shah

Data last updated:

Alpesh Suryakant Shah is a Designated Partner at Lotus Medlife Llp (since 2025). The company operates in Healthcare. Lotus Medlife Llp reported revenue of ₹3.94 Cr (FY 2023).

DIN 11348312
Primary Designation Designated Partner
Industry Healthcare
First Appointment 20 Oct 2025
Largest company Lotus Medlife Llp · ₹3.94 Cr (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner20 Oct 2025₹3.94 Cr (FY 2023)Active

Board colleagues of Alpesh Suryakant Shah

NameDINCompanyDesignation
Nilesh Suryakant Shah08960202Lotus Medlife LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Lotus Medlife Llp
Premium access

Shareholding and investment profile for Alpesh Suryakant Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Alpesh Suryakant Shah

Alpesh Suryakant Shah currently holds 1 directorship: Lotus Medlife Llp (Designated Partner, since 20 Oct 2025, revenue ₹3.94 Cr (FY 2023)).

Alpesh Suryakant Shah was first appointed on 20 Oct 2025 as Designated Partner at Lotus Medlife Llp.

The current boards of Alpesh Suryakant Shah's companies include Nilesh Suryakant Shah (Lotus Medlife Llp).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available